# Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery

> **NCT00814593** · PHASE2 · WITHDRAWN · sponsor: **Lisata Therapeutics, Inc.**

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **BIOLOGICAL:** lymphokine-activated killer cells
- **DRUG:** polifeprosan 20 with carmustine implant

## Key facts

- **NCT ID:** NCT00814593
- **Lead sponsor:** Lisata Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-11
- **Primary completion:** 2011-04
- **Final completion:** 2011-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Hoag Hospital ceased support.
- **Last updated:** 2019-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00814593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00814593, "Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00814593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*